Ertapenem
Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
---|---|---|---|
Antibiotics | Ertapenem | 500mg IV Q24H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
475 | 38 | 4 | 6 | 85-95 | 8.2 | 19 | 30 (N/A) |
References:
- Burkhardt O, Hafer C, Langhoff A et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2009; 24(1), 267-71.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00303
- Embil J, Gin A, Hoban D, Johanson C, Noreddin A, Vercaigne L. Ertapenem: review of a new carbepenm. Expert Review of Anti-Infective Therapy 2005; 3(1), 23.
- Mistry G, Majumdar A, Swan S et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. Journal of clinical pharmacology 2006; 46(10), 1128-38.